Tuesday, May 22, 2018

Neurodegenerative Diseases

Neurodegenerative disease is an umbrella term for a range of conditions which primarily affect the neurons in the human brain.
Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Examples of neurodegenerative diseases include Parkinson’sAlzheimer’s, and Huntington’s disease.
Neurodegenerative diseases are incurable and debilitating conditionsthat result in progressive degeneration and / or death of nerve cells. This causes problems with movement (called ataxias), or mental functioning (called dementias).
Dementias are responsible for the greatest burden of neurodegenerative diseases, with Alzheimer’s representing approximately 60-70% of dementia cases.
The neurodegenerative diseases that JPND focuses on are:
  • Alzheimer’s disease (AD) and other dementias
  • Parkinson’s disease (PD) and PD-related disorders
  • Prion disease
  • Motor neurone diseases (MND)
  • Huntington’s disease (HD)
  • Spinocerebellar ataxia (SCA)
  • Spinal muscular atrophy (SMA)
Source: Neurodegenerationreasearch.edu

Wednesday, May 16, 2018

Secondary Stroke Prevention

Secondary stroke prevention refers to the treatment of individuals who have already had a stroke or transient ischemic attack.
Secondary prevention can be summarized by the mnemonic A, B, C, D, E, as follows:
A - Antiaggregants (aspirin, clopidogrel, extended-release dipyridamole, ticlopidine) and anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin)
B - Blood pressure–lowering medications
C - Cessation of cigarette smoking, cholesterol-lowering medications, carotid revascularization
D - Diet
E – Exercise
Smoking cessation, blood pressure control, diabetes control, a low-fat diet (eg, Dietary Approaches to Stop Hypertension [DASH] or Mediterranean diets), weight loss, and regular exercise should be encouraged.

Monday, May 14, 2018

Stroke Prevention

Join Us at #stroke2018
Primary Prevention- It refers to the treatment of individuals with no history of stroke.
Risk-reduction measures in primary stroke prevention may include the use of antihypertensive medications, anticoagulants, platelet antiaggregants, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), smoking cessation, dietary intervention, weight loss, and exercise.
  • Modifiable risk factors include the following:
  • Hypertension
  • Air pollution
  • Cigarette smoking
  • Diabetes
  • Dyslipidemia
  • Atrial fibrillation
  • Sickle cell disease
  • Postmenopausal HRT
  • Depression
  • Diet and activity
  • Weight and body fat

Ischemic Stroke updated Guidelines

  • Emergency medical services (EMS) leaders should coordinate with medical experts and local, regional, and state agencies to create triage paradigms and protocols to facilitate the rapid identification and assessment of patients with stroke or suspected stroke. This should involve the use of validated stroke screening tools such as the Face Arm Speech Test (FAST), the Cincinnati Prehospital Stroke Scale, or the Los Angeles Prehospital Stroke Screen.
  • In a revision from the 2013 guidelines, the new version recommends the establishment of a door-to-needle (DTN) time goal of ≤60 minutes in ≥50% of AIS patients treated with IV alteplase. “What is new is discussion about DTN times of 45 minutes or less in 50%of patients with acute ischemic stroke” as a secondary goal, Dr Favate noted. “This is most significant as it helps to maximize the critical timeline in stroke triage and initiation of treatment with tPA [tissue plasminogen activator].”
  • A few of the new or revised items in a section on telemedicine include the use of teleradiology and telestroke services for the expedited review of neuroimaging at sites without such capabilities in house; telestroke guidance for tPA administration; and telestroke decision support pertaining to the potential transfer of patients for thrombectomy.
  • It is now recommended that hospitals participate in a stroke data repository to promote adherence to current guidelines, improve patient outcomes, and facilitate quality improvement.
  • Hospitals should establish systems to allow the performance of brain imaging studies within 20 minutes of arrival to the ED in ≥50% of patients for whom IV alteplase and/or thrombectomy may be indicated.
  • Providers should not use the CT hyperdense middle cerebral artery sign as a criterion to withhold tPA from patients who would be candidates otherwise.
                                                                                                                                                       Source: Neurologyadvisor

Thursday, May 10, 2018

Present your Novel Ideas @ Stroke 2018

Lets present your Novel ideas and Innovations to the Neurology world infront of most eminent personalities around the globe @ Vienna, Austria.

There are some interesting Tracks available for the conference which is related to your research stream under Neurodegenerative Disorders & Stroke.

To know more about tracks, Please visit: https://bit.ly/2I0gKTo

Submit your abstracts and get chance to present your talk in the great neurology event "Stroke 2018".

Wednesday, May 9, 2018

Stroke 2018 welcomes you @ Vienna, Austria

Its Great Opportunity to visit Vienna with stroke 2018 conference, during October 22-23, 2018.

There are some interesting tracks are available, which is related to your research field in Neurodegeneration and Stroke.

Do submit you abstracts and get chance to participate in the great occasion.

For more details, Please visit : https://bit.ly/2HrP2Oh

Monday, May 7, 2018


About Conference

On behalf of Pulsus group, we are inviting all the participants from all over the world to attend our conference entitled “ 6th International Conference on Neurodegenerative Disorders and Stroke” to be held on October 22-23, 2018 in Vienna, Austria.

Stroke 2018 has been planning and aiming to stimulate new techniques for treatment of neurodegenerative disorders and stroke that would be beneficial for the neurosurgery.

The conference will be organized around the theme ‘Novel Approaches & Developments in Neurodegenerative Disorders and Stroke’.

Pulsus Group

Pulsus Group is a medical journals publisher that publishes, promotes and disseminates the work of medical researchers in a manner that exemplifies the highest standards in research integrity. Pulsus group is in alliance with Germany and other medical research associations of international level. It publishes medical journals that emphasize on medical specialties like Integrative Medicine, Cardiology, Surgery and Reproductive Medicine. Pulsus group is an association with prominent academic and research societies like Germany Society of Plastic Surgeons, German Society for Aesthetic Plastic Surgery and Germany Society for Surgery of the Hand. 

Pulsus Group is an international level publisher in scientific, technical, and medical journals established within the year 1984 with offices in Ontario and Canada, India has reaped Andrew John publishing and openaccessjournals.com to expand its Open Access publishing through its 50+ journals in association with 20+ International medical and scientific societies.

Target Audience
  • Directors/Managers/CEO’s
  • Presidents & Vice Presidents
  • Neurologists
  • Neurosurgeons
  • Neurology doctors
  • Scientists and professors
  • Neuro research scholars
  • Medical Colleges
  • Research faculty
  • Academic Scientists
  • Students
  • Diagnostic laboratory professionals
  • Business Entrepreneurs
  • Industry professionals
  • Brand Manufacturers/ Marketers of Consumer Products
  • Marketing, Advertising and Promotion Agency Executives

Why to attend?
  • 10+ Keynote Speaker Session
  • 50+ speaker faculty over 2 full days sharing Evidence Based Nursing practice
  • 5+ Workshops
  • 13 Interactive sessions
  • Mixture of Health care units and Academia Delegates
  • Networking

Conference Highlights